At the same time, through two separate orders, Sebi has also slapped "a penalty of Rs 3 lakh" each on one Jagdish Ramanlal Patel and one C Shah Champaklal for fraudulent trading in shares of Aarey Drugs and Pharmaceuticals.
The Securities and Exchange Board of India (Sebi) has found that Manish Ratilal Shah had in collusion with the some other connected entities executed synchronised and reversal trades in scrip of the four companies.
Accordingly, in an order dated September 9, the market regulator has imposed "a consolidated penalty of Rs 22 lakh on Manish Ratilal Shah".
Similarly, based on its probe, Sebi also concluded that Patel and Champaklal "had executed synchronised trades in the scrip of Aarey Drugs and Pharmaceuticals Ltd" which had resulted in creation of artificial volume in the shares of the company leading to false and misleading appearance of trading in the scrips.
The case relates to Sebi probe into the trading in shares of the four companies including Aarey Drugs and Pharmaceuticals for the period January 1-August 31, 2009.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
